ArticleAdvances in therapy2015

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries.

Ashok Jha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.